BACKGROUND AND AIMS: @entity1340 is commonly used to treat moderate to moderately-severe @entity158 in adults. We aimed to analyze the clinical relevance of @entity1340 use during weaning and extubation in @entity1 with @entity131 ( @entity131 ). MATERIAL AND METHODS: A retrospective observational study was conducted and included all the intubated @entity131 @entity1 at the level I @entity130 center between 2011 and 2012. Data included @entity1 's demographics, mechanism of injury (MOI), Glasgow @entity772 Scale (GCS), injury severity score, length of @entity1213 ( @entity1213 ) stay length of stay (LOS), @entity2146 scale, analgesics, failure of extubation and tracheostomy. @entity1 were divided into two groups based on whether they received @entity1340 (Group 1) or not (Group 2) during ventilatory weaning. Chi-square and Student's t-tests were used for categorical and continuous variables; respectively. Logistic regression analysis was performed for predictors of @entity2146 in @entity1213 . RESULTS: The study included 393 @entity131 @entity1 ; the majority (96%) was males with a mean age of 33.6    14 years. The most common MOI were motor vehicle crash (39%), fall (29%) and pedestrian (17%). The associated injuries were mainly chest (35%) and abdominal (16%) @entity130 . @entity1340 was administered in 51.4% of @entity131 @entity1 . Tracheostomy was performed in 12.4% cases. Agitation was observed in 34.2% cases. Group 1 @entity1 had significantly lower age (31.6    12.4 vs. 35.7    15.6; P = 0.005) and head AIS (3.5    0.8 vs. 3.9    0.9; P = 0.001) compared to Group 2. The incidence of @entity2146 , @entity1213 and hospital LOS were higher in Group 1. Failure of extubation and tracheostomy were reported more frequently in Group 1 (P = 0.001). On multivariate analysis, @entity1340 use was an independent predictor for @entity2146 (adjusted odds ratio 21; P = 0.001), followed by low GCS. CONCLUSION: @entity1 with @entity131 who received @entity1340 are more likely to develop @entity2146 , undergo tracheostomy and to have longer hospital LOS. Therefore, an extensive risk-benefit assessment would help to attain maximum efficacy of the drug in @entity131 @entity1 .

@entity1340 in XXXX : Should we continue to use it?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury'] @entity1340 :: ('MESH:D014147', 'Chemical') :: ['tramadol', 'Tramadol'] @entity772 :: ('MESH:D003128', 'Disease') :: ['Coma'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['agitation'] @entity1213 :: ('MESH:D012555', 'Disease') :: ['Intensive Care Unit', 'ICU'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity131 :: (MESH:D001930,Disease) :: ['traumatic brain injury']
